

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/160721 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) C12N 5/10 (2006.01)
C07K 16/28 (2006.01) C07K 1/00 (2006.01)
C07K 14/54 (2006.01) A61P 35/00 (2006.01)
C12N 15/62 (2006.01) A61K 38/20 (2006.01)
C12N 15/63 (2006.01)

(21) International Application Number:

PCT/CN2023/078743

(22) International Filing Date:

28 February 2023 (28.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/078326

28 February 2022 (28.02.2022) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth A91 X56F (IE).

(72) Inventors: **LIANG, Yu**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **SUN, Mengmeng**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **WU, Lei**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **XIN, Ruipu**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **XU, Jianqing**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **GU, Jijie**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Xicheng District, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HETERODIMERIC POLYPEPTIDE COMPLEXES COMPRISING IL-15 VARIANTS AND USES THEREOF

(57) Abstract: Provided in the present disclosure are IL-15 variants, IL-15/IL-15R α -Fc fusion proteins comprising the IL-15 variants and IL-15/IL-15R α fusion protein comprising the IL-15 variants the methods of producing the same and the uses thereof. The IL-15 variants, fusion proteins, and polypeptide complexes of the disclosure can be used as a potent agent for the treatment of cancers and infectious diseases.

WO 2023/160721 A1